Key result
Aliskiren pretreatment at 100 mg/kg/day significantly reduced systolic blood pressure by 16.4% and heart rate by 16.8% compared to control in rats with daunorubicin-induced cardiomyopathy.
Why the study?
Clinical use of daunorubicin is limited by cardiomyopathy and heart failure, and the renin-angiotensin system plays a role in cardiac hypertrophy and reperfusion injury.
Does aliskiren prevent hemodynamic deterioration in a rat model of daunorubicin-induced acute cardiomyopathy?
Does aliskiren prevent hemodynamic deterioration in a rat model of daunorubicin-induced acute cardiomyopathy?
Aliskiren pretreatment at 50 and 100 mg/kg/day significantly protected against daunorubicin-induced hemodynamic changes in a rat model of acute cardiomyopathy.
Hypothesis-generating for aliskiren in daunorubicin cardiotoxicity; prospective trials needed before clinical use.
Daunorubicin ((DNR)) used in oncological practice against a wide variety of solid organ tumors and hematologic malignancies, including leukemia, lymphoma, breast cancer, lung cancer, multiple myeloma and sarcoma. however clinical use of this agent is limited due to cardiomyopathy and cardiac heart failure. one of the important player in the development of cardic hypertrophy and reperfusion injury is renin-angiotensin system. Aliskiren (ALK) a recent drug of a direct inhibitor of the renin enzyme. It Protect cardiomyopathy by the inhibition of the renin activity. Present study is towards the evaluation of protective effcets of ALK 50 and 100 mg/kg/day in rats. The systolic, diastolic, mean BP and heart rate were significantly (P< 0.01) increased in DNR control group as compared to normal control group. Thus the results provide clear evidence that the ALK pretreatment offered significant protection against DNR-induced Hemodynamic parameters changes. Keywords: Daunorubicin, Cardiomyopathy, Aliskiren, Telmisartan and Hemodynamic parameters
No takes yet. Share an insight, caveat, or question.
Ansari et al. (2019) studied Daunorubicin-induced acute cardiomyopathy (n=48). Aliskiren vs. Daunorubicin control was evaluated on Systolic blood pressure (mm Hg) (16.4% reduction, p=<0.01). Aliskiren pretreatment at 100 mg/kg/day significantly reduced systolic blood pressure by 16.4% and heart rate by 16.8% compared to control in rats with daunorubicin-induced cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: